高级检索
    郭汉国, 陈菲莉, 张芬, 罗东兰, 魏小娟, 黄玲, 江新苗, 刘思初, 梁湛丽, 刘艳辉, 李文瑜. 原发耐药弥漫大B细胞淋巴瘤36例临床分析[J]. 循证医学, 2018, 18(4): 236-240. DOI: 10.12019/j.issn.1671-5144.2018.04.012
    引用本文: 郭汉国, 陈菲莉, 张芬, 罗东兰, 魏小娟, 黄玲, 江新苗, 刘思初, 梁湛丽, 刘艳辉, 李文瑜. 原发耐药弥漫大B细胞淋巴瘤36例临床分析[J]. 循证医学, 2018, 18(4): 236-240. DOI: 10.12019/j.issn.1671-5144.2018.04.012
    shu
    GUO Han-guo, CHEN Fei-li, ZHANG Fen, LUO Dong-lan, WEI Xiao-juan, HUANG Ling, JIANG Xin-miao, LIU Si-chu, LIANG Zhan-li, LIU Yan-hui, LI Wen-yu. Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2018, 18(4): 236-240. DOI: 10.12019/j.issn.1671-5144.2018.04.012
    Citation: GUO Han-guo, CHEN Fei-li, ZHANG Fen, LUO Dong-lan, WEI Xiao-juan, HUANG Ling, JIANG Xin-miao, LIU Si-chu, LIANG Zhan-li, LIU Yan-hui, LI Wen-yu. Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2018, 18(4): 236-240. DOI: 10.12019/j.issn.1671-5144.2018.04.012
    shu

    原发耐药弥漫大B细胞淋巴瘤36例临床分析

    Clinical Analysis of 36 Cases with Primary Refractory Diffuse Large B Cell Lymphoma

      摘要
    • 摘要: 目的 分析原发耐药弥漫大B细胞淋巴瘤的临床特征和治疗方法,探讨患者的疗效和主要预后影响因素。 方法 对广东省人民医院淋巴瘤科2006年3月至2014年12月收治的36例原发耐药弥漫大B细胞淋巴瘤患者的临床特点、治疗方案、疗效及预后进行回顾性分析。 结果 36例原发耐药弥漫大B细胞淋巴瘤患者中,一线治疗方案均为阿霉素为主的化疗方案 ± 利妥昔单抗,5例患者未接受挽救治疗,二线治疗方案有DICE、GDP、DHAP、CEPP、来那度胺以及GA101,接受治疗患者的中位无进展生存时间（距首次复发）为1.7个月,2年无进展生存率为5.0%,中位总生存时间（距首次复发）为7.9个月,2年总生存率为25.9%。单因素分析显示复发时国际预后指数高、大病灶、B症状对患者生存率有影响,差异有统计学意义。仅有3名患者获得>30个月的长期生存,2名患者均使用新的靶向药物。 结论 原发耐药弥漫大B细胞淋巴瘤患者预后差,难以从常规挽救化疗中得到获益。

       

      Abstract: Objective To investigate the survival ratio and factors affecting prognosis by analyzing clinical data. Methods Clinical data of 36 cases with primary refractory diffuse large B cell lymphoma admitted to Guangdong General Hospital were retrospectively analyzed. Results 5 patients refused further salvage treatment. First-line chemotherapy are anthracycline-based regimens combined with or without rituximab. The salvage treatment regimens are DICE, GDP, DHAP, CEPP, Lenalidomide and GA101. Median second progression free survival time is 1.7 months with 2 year second progression free survival rate being 5.0%. Median second overall survival time is 7.9 months with 2 year second overall survival rate being 25.9%. Univariate analyses showed that high IPI, bulky disease and B symptom influenced the prognosis. Conclusions Patients with primary refractory diffuse large B cell lymphoma have poor prognosis and can't benefit from regular salvage chemotherapy.

       

      • HTML全文
      • 参考文献(16)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回